LLY — long thesis
Thesis
LLY defensive pharma long — GLP-1/incretin franchise leader (Zepbound/Mounjaro) plus deep cardiometabolic pipeline; held as rate-shielded defensive-growth ballast. Partial profit-take was executed Aug 26 at the 10-15%+ band; remaining core managed on trail. FRESH POSITIVE CATALYSTS (Sep 22): LLY received full FDA approval for Inluriyo in ESR1-mutated breast cancer (regulatory/bullish), and the CEO said its oral GLP-1 Foundayo is winning ~1/3 of new oral GLP-1 scripts (product/bullish/high) — validating the oral-incretin land-grab against competitors. Offsetting overhang persists: renewed drug-pricing/Medicare scrutiny (most-favored-nation, CMS lab payment cuts). Net: franchise fundamentals strengthening; hold the retained core as ballast on trail, do not re-trim on the same band.
Triggers
Entry: Position already held — managed as core defensive ballast. No adds above formation size while the hawkish-rate regime persists.
Exit: Remaining core on trail — exit in full on a close 10% below the post-trim high-water mark or on a close below cost basis +5%. Do not re-trim on the original 10-15% band (already executed). Full take-profit on another 10% extension beyond the trim level. Trim on a GLP-1 franchise setback or if the White House drug-pricing terms are announced with quantified material GLP-1 price cuts.
Invalidation: GLP-1 franchise setback (safety/regulatory/reimbursement or competitive displacement). Healthcare underperforms SPY for 3+ consecutive weeks. Close below recent support on volume. Rate regime turns decisively dovish, evaporating the defensive rotation bid.
Cited evidence
News
- LLY Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
- LLY Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'
- LLY 'Eli Lilly CEO Says Co To Halve Original Planned Investment Of €2.3 Billion In Germany' - Handelsblatt
- LLY Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
- AAPL Apple Unveils AI Push Beyond Siri With Smart Writing, Accessibility Features
- LLY Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
- LLY Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection
Macro
- 'White House to Announce New Drug Pricing Deals With Biotechs' - Bloomberg
- Healthcare and Technology Lead Current Order Flow Activity
- Semi Mania Gets A Reality Check From South Korea; Investors Should Pay Attention To Shift In AI Tokens
- Nasdaq 100 Plunges Over 3% On Rate Hike Jitters, Bitcoin's Bloodbath Worsens: Stock Market Today
- Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
- Ed Yardeni's Fed Bombshell: Rate Hike Coming In July
- Nasdaq 100 Falls 1% As 30-Year Yields Spike To 19-Year Highs: Stock Market Today
- Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today
- Inflation Jumps To 3.8% In April, Kills Fed Rate-Cut Hopes (UPDATED)
- Stock Market Today: S&P 500, Nasdaq 100 Futures Drop As April Inflation Runs Hotter Than Expected— Zoominfo, Gitlab In Focus (UPDATED)